Principles

Our Principles:

1. We harness science and entrepreneurialism to envision alternative futures, beginning with seemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology. We call this process pioneering.

2. We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated.

3. We attract, develop, and retain the top scientific, entrepreneurial, and managerial talent in the world.

4. We combine innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.

5. We are the founders, primary resource providers, and principal owners of our companies and take responsibility for their long-term success by providing them with the full resources of our ecosystem.

6. We are insurgents, conceiving innovations outside current markets and solutions, far beyond the adjacent, continuous innovations that incumbents seek.

7. We found businesses that own proprietary platforms that enable years of important new products across multiple areas.

8. We deliver extraordinary returns to our capital partners by creating the world’s most innovative and valuable life sciences companies.

The Flagship team conceives, resources, and builds life sciences companies that invent breakthrough technologies, each based on an original product platform, to transform health care and sustainability.

Our unique model combines scientific creativity, technological ingenuity, systematic entrepreneurship, executive leadership, professional capital management, and a vast network of expertise into a single institution that produces first-in-category companies through an emergent, evolutionary methodology. We call this process pioneering.

Over nearly two decades, this approach has enabled Flagship to originate and foster the development of around 100 science-based companies, resulting in more than $30 billion in aggregate value, thousands of patents, and a pipeline of more than 50 clinical development programs. With more than $3 billion in private capital raised and managed by Flagship, we have financed our portfolio with $1.5 billion and attracted another $11 billion from follow-on investors.